NCT01183780已完成3 期
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,072
- 试验地点
- 1
- 主要终点
- Overall Survival (OS)
研究概览
简要总结
The purpose of this study is to compare overall survival in participants with metastatic colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed colorectal cancer, excluding primary tumors of appendiceal origin (participants are eligible to enroll irrespective of KRAS mutation status)
- •Confirmed metastatic colorectal cancer (Stage IV)
- •The participant has received first-line combination therapy of bevacizumab, oxaliplatin, and a fluoropyrimidine for metastatic disease and, a) Experienced radiographic disease progression during first-line therapy, or b) Experienced radiographic disease progression ≤6 months after the last dose of first-line therapy, or c) Discontinued part or all of first-line therapy due to toxicity and experienced radiographic disease progression ≤6 months after the last dose of first-line therapy. Note that a participant must have received a minimum of 2 doses of bevacizumab as part of a first-line regimen containing chemotherapy; in addition, a participant must have received at least 1 cycle of first-line therapy that included bevacizumab, oxaliplatin and a fluoropyrimidine in the same cycle. Note that a participant must not have received more than 2 different fluoropyrimidines as part of a first-line regimen; disease progression is not an acceptable reason for discontinuing 1 fluoropyrimidine and starting a second fluoropyrimidine
- •Receipt of no more than 2 prior systemic chemotherapy regimens in any setting (only 1 prior regimen for metastatic disease is permitted). For participants with rectal cancer, sequential neoadjuvant and adjuvant therapy will count as a single systemic regimen. Note that rechallenge with oxaliplatin is permitted and will be considered part of the first-line regimen for metastatic disease, both initial oxaliplatin treatment and subsequent rechallenge are considered as 1 regimen
- •Measurable or nonmeasurable disease based on the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
- •Adequate hematologic, renal and hepatic function
- •Adequate coagulation function [International Normalized Ratio (INR) ≤1.5 and Partial Thromboplastin Time (PTT) or activated PTT (aPTT) ≤1.5 x upper limit of normal (ULN)). Participants on full-dose anticoagulation must be on a stable dose of anticoagulant therapy and if on oral anticoagulation, must have an INR ≤3 and have no clinically significant active bleeding or pathological condition that carries a high risk of bleeding
- •Consent to provide a historical colorectal cancer tissue sample for assessment of biomarkers and the tumor tissue sample is available
- •Ability to provide signed informed consent
排除标准
- •Receipt of bevacizumab ≤28 days prior to randomization
- •Receipt of any investigational therapy for non-oncology clinical indication ≤28 days prior to randomization
- •Receipt of any previous systemic therapy, other than a combination of bevacizumab, oxaliplatin, and a fluoropyrimidine, for first-line treatment of metastatic colorectal cancer
- •Known leptomeningeal disease or brain metastases or uncontrolled spinal cord compression (currently or in the past)
- •Experience of any arterial thrombotic or arterial thromboembolic events, including, but not limited to, myocardial infarction, transient ischemic attack, or cerebrovascular accident, ≤12 months prior to randomization
- •Pregnant (confirmed by serum beta human chorionic gonadotropin (ß HCG) test ≤7 days prior to randomization) or lactating
- •History of inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤12 months prior to randomization
- •Acute or subacute bowel obstruction or history of chronic diarrhea which is considered clinically significant in the opinion of the investigator
- •Grade 3 or higher bleeding event ≤3 months prior to randomization
- •Experience of any of the following during first-line therapy with a bevacizumab-containing regimen: an arterial thrombotic/thromboembolic event, Grade 4 hypertension, Grade 3 proteinuria, a Grade 3-4 bleeding event, or bowel perforation
- •Known history or clinical evidence of Gilbert's Syndrome, or is known to have any of the following genotypes: UGT1A1*6/*6, UGT1A1*28/*28, or UGT1A1*6/*28
- •Known allergy to any of the study treatment components, including any components used in the preparation of ramucirumab, or other contraindication to receive the study treatments
- •Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or clinical meaningful ascites resulting from cirrhosis; Clinically meaningful ascites is defined as ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis
研究组 & 干预措施
FOLFIRI + Ramucirumab
Experimental
干预措施: Ramucirumab (Biological)
FOLFIRI + Ramucirumab
Experimental
干预措施: Irinotecan (Drug)
FOLFIRI + Ramucirumab
Experimental
干预措施: Folinic Acid (Drug)
FOLFIRI + Ramucirumab
Experimental
干预措施: 5-Fluorouracil (Drug)
FOLFIRI + Placebo
Placebo Comparator
干预措施: Placebo (Biological)
FOLFIRI + Placebo
Placebo Comparator
干预措施: Irinotecan (Drug)
FOLFIRI + Placebo
Placebo Comparator
干预措施: Folinic Acid (Drug)
FOLFIRI + Placebo
Placebo Comparator
干预措施: 5-Fluorouracil (Drug)
结局指标
主要结局
Overall Survival (OS)
时间窗: Randomization to Date of Death from Any Cause Up to 39.36 Months
OS was defined as the time in months from the date of randomization to the date of death from any cause. For participants not known to have died as of the cut-off date, OS was censored at the last known date alive.
次要结局
- Progression-free Survival (PFS) Time(Randomization to Measured PD or Date of Death from Any Cause Up to 38.01 Months)
- Percentage of Participants Achieving an Objective Response (Objective Response Rate)(Randomization until Disease Progression Up to 38.01 Months)
- Change From Baseline in European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30 Global Health Status(Baseline Up to 171 Weeks)
- Change From Baseline in EuroQol- 5D (EQ-5D)(Baseline and 30-Day Follow-Up (FU) up to 171 Weeks)
- Percentage of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies(Cycles 1, 3, 5, and 30-Day FU)
- Observed Maximum Concentration (Cmax) and Observed Minimum Concentration (Cmin) of Ramucirumab(Preinfusion and 1 hour postinfusion in Cycles 3, 5, 9, 13, and 17)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of Ramucirumab or Icrucumab in Colorectal CancerRectal CancerColon CancerNCT01111604Eli Lilly and Company158
已完成
3 期
Study of Cemiplimab in Adults With Cervical CancerSquamous Cell Carcinoma (SCC)Recurrent or Metastatic, Platinum-refractory Cervical CancerNCT03257267Regeneron Pharmaceuticals608
进行中（未招募）
不适用
Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer MetastasesMulti-organ Metastatic Colorectal CancerNCT01792934Radboud University Medical Center478
已完成
3 期
Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal CancerColorectal CancerNCT00061815Eli Lilly and Company102
已完成
3 期
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck CancersCarcinoma, Squamous Cell of the Head and NeckNCT01166542Oncolytics Biotech167